Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284–96.

Article  PubMed  PubMed Central  Google Scholar 

Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RC Jr., Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharm. 2018;81:17–38.

Article  CAS  Google Scholar 

Guo Q, Yang Q, Li J, Liu G, Nikoulin I, Jia S. Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening. Anticancer Drugs. 2020;31:101–9.

Article  CAS  PubMed  Google Scholar 

McCloskey CW, Rodriguez GM, Galpin KJC, Vanderhyden BC. Ovarian cancer immunotherapy: preclinical models and emerging therapeutics. Cancers. 2018;10:244.

Article  PubMed  PubMed Central  Google Scholar 

Awada A, Ahmad S, McKenzie ND, Holloway RW. Immunotherapy in the treatment of platinum-resistant ovarian cancer: current perspectives. Onco Targets Ther. 2022;15:853–66.

Article  PubMed  PubMed Central  Google Scholar 

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. New Engl J Med. 2015;373:1627–39.

Article  CAS  PubMed  Google Scholar 

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. New Engl J Med. 2015;372:2521–32.

Article  CAS  PubMed  Google Scholar 

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol. 2017;35:2117–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. New Engl J Med. 2017;376:1015–26.

Article  CAS  PubMed  Google Scholar 

Park J, Lee JY, Kim S. How to use immune checkpoint inhibitor in ovarian cancer? J Gynecol Oncol. 2019;30:e105.

Article  PubMed  PubMed Central  Google Scholar 

Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33:4015–22.

Article  CAS  PubMed  Google Scholar 

Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA. 2008;105:3005–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC Jr., et al. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol Oncol. 2001;80:245–53.

Article  CAS  PubMed  Google Scholar 

Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, et al. TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 2013;73:5016–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D. Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene. 2012;31:2521–34.

Article  CAS  PubMed  Google Scholar 

Deng J, Wang L, Chen H, Hao J, Ni J, Chang L, et al. Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget. 2016;7:55771–88.

Article  PubMed  PubMed Central  Google Scholar 

Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Fuso NI, et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer. 2013;49:520–30.

Article  CAS  PubMed  Google Scholar 

Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol. 1998;64:275–90.

Article  CAS  PubMed  Google Scholar 

Singh M, Loftus T, Webb E, Benencia F. Minireview: regulatory T cells and ovarian cancer. Immunol Investig. 2016;45:712–20.

Article  CAS  Google Scholar 

Trotta R, Dal Col J, Yu J, Ciarlariello D, Thomas B, Zhang X, et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol. 2008;181:3784–92.

Article  CAS  PubMed  Google Scholar 

Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol. 2010;117:366–72.

Article  CAS  PubMed  Google Scholar 

Zhang Q, Hou X, Evans BJ, VanBlaricom JL, Weroha SJ, Cliby WA. LY2157299 monohydrate, a TGF-betaR1 inhibitor, suppresses tumor growth and ascites development in ovarian cancer. Cancers. 2018;10:260.

Article  PubMed  PubMed Central  Google Scholar 

Newsted D, Banerjee S, Watt K, Nersesian S, Truesdell P, Blazer LL, et al. Blockade of TGF-beta signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models. Oncoimmunology. 2019;8:e1539613.

Article  PubMed  Google Scholar 

Bartlett JM, Langdon SP, Scott WN, Love SB, Miller EP, Katsaros D, et al. Transforming growth factor-beta isoform expression in human ovarian tumours. Eur J Cancer. 1997;33:2397–403.

Article  CAS  PubMed  Google Scholar 

Nakanishi Y, Kodama J, Yoshinouchi M, Tokumo K, Kamimura S, Okuda H, et al. The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer. Int J Gynecol Pathol. 1997;16:256–62.

Article  CAS  PubMed  Google Scholar 

Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, et al. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS ONE. 2013;8:e80063.

Article  PubMed  PubMed Central  Google Scholar 

Knudson KM, Hicks KC, Luo X, Chen JQ, Schlom J, Gameiro SR. M7824, a novel bifunctional anti-PD-L1/TGFbeta Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. Oncoimmunology. 2018;7:e1426519.

Article  PubMed  PubMed Central  Google Scholar 

Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-beta. Sci Transl Med. 2018;10:eaan5488.

Article  PubMed  Google Scholar 

David JM, Dominguez C, McCampbell KK, Gulley JL, Schlom J, Palena C. A novel bifunctional anti-PD-L1/TGF-beta Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. Oncoimmunology. 2017;6:e1349589.

Article  PubMed  PubMed Central  Google Scholar 

Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, et al. Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFbeta, in advanced solid tumors. Clin Cancer Res. 2018;24:1287–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cho BC, Daste A, Ravaud A, Salas S, Isambert N, McClay E, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. J Immunother Cancer. 2020;8:e000664corr1.

Article  Google Scholar 

Paz-Ares L, Kim TM, Vicente D, Felip E, Lee DH, Lee KH, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial. J Thorac Oncol. 2020;15:1210–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoo C, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, et al. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer. J Immunother Cancer. 2020;8:e000564.

Article  PubMed  PubMed Central